191 related articles for article (PubMed ID: 33741858)
1. 18F-FDG PET/CT imaging features of patients with multicentric Castleman disease.
Jiang Y; Hou G; Zhu Z; Huo L; Li F; Cheng W
Nucl Med Commun; 2021 Jul; 42(7):833-838. PubMed ID: 33741858
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters.
Polizzotto MN; Millo C; Uldrick TS; Aleman K; Whatley M; Wyvill KM; O'Mahony D; Marshall V; Whitby D; Maass-Moreno R; Steinberg SM; Little RF; Yarchoan R
J Infect Dis; 2015 Oct; 212(8):1250-60. PubMed ID: 25828248
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the clinical manifestations and 18F-FDG PET-CT findings in 40 patients with histiocytic necrotizing lymphadenitis.
Zhang R; Liang L; Li D; Bai Y; Li X
Medicine (Baltimore); 2021 Sep; 100(35):e27189. PubMed ID: 34477179
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET/ CT for initial staging and response assessment in Castleman disease - retrospective single-center study of 29 cases.
Koukalová R; Selingerová I; Řehák Z; Adam Z; Szturz P
Klin Onkol; 2021; 34(2):120-127. PubMed ID: 33906360
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. The systemic impact of different COVID-19 vaccines in 2-[18F] FDG-PET/CT.
Nazerani-Zemann T; Pernthaler B; Schwantzer G; Gstettner C
Sci Rep; 2023 Dec; 13(1):21838. PubMed ID: 38071353
[TBL] [Abstract][Full Text] [Related]
7. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.
Barker R; Kazmi F; Stebbing J; Ngan S; Chinn R; Nelson M; O'Doherty M; Bower M
Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):648-52. PubMed ID: 19050873
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT used in identifying adult-onset Still's disease in connective tissue diseases.
Zhou X; Li Y; Wang Q
Clin Rheumatol; 2020 Sep; 39(9):2735-2742. PubMed ID: 32180040
[TBL] [Abstract][Full Text] [Related]
10.
He L; Chen Y; Tan X; Sun X; Zhang Q; Luo H; Jiang L
Jpn J Radiol; 2023 Jan; 41(1):98-107. PubMed ID: 35895223
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT in patients with adult-onset Still's disease.
Dong MJ; Wang CQ; Zhao K; Wang GL; Sun ML; Liu ZF; Xu L
Clin Rheumatol; 2015 Dec; 34(12):2047-56. PubMed ID: 25711875
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy.
Zanoni L; Varani S; Attard L; Morigi JJ; Vanino E; Ortalli M; Fonti C; Viale P; Re MC; Fanti S; Ambrosini V
Ann Nucl Med; 2019 Sep; 33(9):716-723. PubMed ID: 31254270
[TBL] [Abstract][Full Text] [Related]
13. Metabolic characteristics of Castleman disease on 18F-FDG PET in relation to clinical implication.
Lee ES; Paeng JC; Park CM; Chang W; Lee WW; Kang KW; Chung JK; Lee DS
Clin Nucl Med; 2013 May; 38(5):339-42. PubMed ID: 23429387
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT findings in patients with Kikuchi disease.
Kong E; Chun K; Hong Y; Hah J; Cho I
Nuklearmedizin; 2013; 52(3):101-6. PubMed ID: 23681151
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT findings in endometrial cancer patients: the correlation between SUVmax and clinicopathologic features.
Boonya-ussadorn T; Choi WH; Hyun J; Kim SH; Chung SK; Yoo IeR
J Med Assoc Thai; 2014 Feb; 97 Suppl 2():S115-22. PubMed ID: 25518184
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
Ömür Ö; Baran Y; Oral A; Ceylan Y
Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
[TBL] [Abstract][Full Text] [Related]
18. PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma.
Rao L; Wang X; Zong Z; Chen Z; Shi X; Yi C; Zhang X; Yang Z
Medicine (Baltimore); 2016 May; 95(20):e3750. PubMed ID: 27196500
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature.
Yamashita H; Kubota K; Takahashi Y; Minamimoto R; Morooka M; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2014 Jul; 24(4):645-50. PubMed ID: 24252024
[TBL] [Abstract][Full Text] [Related]
20. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study.
van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]